CTLA4 and small cell lung carcinoma: A new therapeutic approach for LS-SCLC includes the combination of an anti-TGIT monoclonal antibody with immune checkpoint inhibitors, such as anti-PD-L1, anti-PD1, and anti-CTLA4 antibodies.